Sweeping FDA Changes Could Have “Disastrous Consequences” For Biotech Investment
Lowering the bar on drug approval standards would create a challenging environment for biotech investors, warned Jonathan Leff, a partner at the health care investment firm Deerfield, during the BIO CEO & Investor Conference.
You may also be interested in...
Alex Azar talks about price negotiation in Medicare Part B, whether his biopharma industry ties would influence his decisions as head of HHS, insulin price increases and importation during the first of his confirmation hearings.
US President targeted drug prices again on Twitter, and later in the day House Democratic Rep. Elijah Cummings announced a meeting with Trump March 8 to discuss lowering drug prices.
Analyst poll of 53 drug companies indicates broad support for Scott Gottlieb compared to three other known candidates for FDA Commissioner.